Search results
Results From The WOW.Com Content Network
Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and ... this was followed in July 2016 by the layoff of another 100 ...
Arena Pharmaceuticals (ARNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the third quarter of 2019 while revenues beat estimates.
Arena Pharmaceuticals, Inc. (ARNA) delivered earnings and revenue surprises of -32.64% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ...
Arena Pharmaceuticals (NAS: ARNA) is revving up for the launch of its obesity drug, Belviq. The drug was the first obesity drug approved earlier this year but got held back by DEA scheduling while ...
Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.
What: Shares of obesity-fighting biotech Arena. Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call: 800-290-4726 more ways to reach us ...
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for the second quarter of 2020. Clinical progress remains on track amid COVID-19 pandemic.